head and neck cancers form almost a quarter of the cancer burden in India. Several of such patients are dependent on their voice for livelihood (eg lawyers). Is it possible to offer them good chance of cure from cancer while still preserving their voice?
The answer is yes, in specific instances.
Recently neoadjuvant chemotherapy for larynx preservation with cisplatin, 5-fluorouracil and docetaxel (TPF) was compared with cisplatin and 5-fluorouracil (PF) in a total of 213 patients in this phase III trial.
Responders underwent subsequent radiation therapy, while nonresponders underwent laryngectomy.
The three drug chemotherapy group had higher rates of larynx preservation at 5 and 10 years compared with the PF group (74.0% vs 58.1% and 70.3% vs 46.5%, respectively; P = .01). They also experienced fewer grade 3 or 4 late toxicities of the larynx than the PF arm (9.3% vs 17.1%; P = .038).
That is why Asian Cancer Institute is quickly gaining impressive reputation of putting patient first and striving to ensure optimal quality of life.